Related Experiment Videos
Impact and modulation of nasal obstruction
1Ear, Nose, and Throat Clinic, Vienna, Austria.
Allergy
|December 21, 2002
Summary
Desloratadine effectively treats nasal obstruction in seasonal allergic rhinitis by inhibiting inflammatory mediators. Clinical trials show desloratadine significantly improves nasal airflow and reduces symptom severity compared to placebo.
Area of Science:
- Allergy and Immunology
- Pharmacology
Background:
- Nasal obstruction is a primary symptom of allergic rhinitis, driven by early and late-phase allergic reactions.
- Desloratadine demonstrates in vitro inhibition of key inflammatory mediators involved in allergic responses.
Purpose of the Study:
- To evaluate the efficacy of desloratadine in alleviating nasal obstruction in patients with seasonal allergic rhinitis.
- To assess both objective and subjective measures of nasal obstruction under controlled allergen exposure.
Main Methods:
- Conducted double-blind, placebo-controlled, randomized, crossover trials.
- Utilized controlled allergen challenges in patients with seasonal allergic rhinitis.
- Administered single and multiple doses (5 mg daily for 7 days) of desloratadine.
Main Results:
- Desloratadine (5 mg) significantly improved total symptom and nasal obstruction scores versus placebo in single-dose studies (P ≤ 0.02).
- Multiple-dose treatment with desloratadine (5 mg daily) showed less deterioration in nasal airflow (P < 0.05) and obstruction severity (P < 0.03) post-allergen challenge.
Conclusions:
- Desloratadine is an effective treatment for reducing nasal obstruction severity in seasonal allergic rhinitis.
- The drug's ability to inhibit early- and late-phase inflammatory mediators contributes to its therapeutic effect.